Cheapest Wegovy Or Saxenda UK - Compare Prices

Our Pricing

Wegovy Or Saxenda: Which Weight Loss Injection Is Right For You?

Choosing between wegovy or saxenda is one of the most common questions we receive from patients seeking prescription weight loss treatment in the UK. Both are GLP-1 receptor agonist injections licensed by the MHRA for chronic weight management, but they differ significantly in their active ingredient, dosing frequency, efficacy profile, and cost. As a UK-registered pharmacy with thousands of weight loss consultations completed, we've seen firsthand how understanding these differences helps patients make informed decisions alongside their prescriber.

What Is The Difference Between Wegovy Or Saxenda?

The fundamental difference between wegovy or saxenda lies in their active pharmaceutical ingredients and molecular design. Wegovy contains semaglutide, a longer-acting GLP-1 receptor agonist with a half-life of approximately 7 days, allowing for once-weekly subcutaneous injection [1]. Saxenda contains liraglutide, a shorter-acting GLP-1 analogue with a half-life of 13 hours, requiring daily subcutaneous administration [2]. Both medications work by mimicking the incretin hormone GLP-1, which regulates appetite, slows gastric emptying, and enhances insulin secretion, but their pharmacokinetic profiles create distinct dosing and adherence considerations.

In clinical practice, we observe that the once-weekly dosing of Wegovy often improves treatment adherence compared to Saxenda's daily injections, particularly for patients with busy lifestyles or needle anxiety. However, Saxenda's shorter half-life may offer advantages for patients who experience side effects, as the medication clears the system more rapidly if dose adjustment or discontinuation becomes necessary. Both treatments are available at Cured Pharmacy from £69.00 for Wegovy and from £69.00 for Saxenda, subject to prescriber approval following online clinical assessment.

Wegovy Or Saxenda: Which Achieves Greater Weight Loss?

When comparing wegovy or saxenda for weight loss efficacy, clinical trial data demonstrates a clear difference in average outcomes. The STEP 1 trial showed that patients taking Wegovy (semaglutide 2.4mg weekly) achieved an average weight loss of 14.9% of initial body weight over 68 weeks, compared to 2.4% with placebo [1]. In contrast, the SCALE Obesity and Prediabetes trial reported that Saxenda (liraglutide 3mg daily) produced an average weight loss of 8.0% over 56 weeks, versus 2.6% with placebo [2].

These figures represent averages across large trial populations, and individual results vary considerably based on baseline BMI, adherence, dietary modifications, and physical activity levels. In our clinical experience at Cured Pharmacy, patients on either medication who combine treatment with structured lifestyle changes typically achieve superior outcomes to medication alone. While Wegovy demonstrates higher average weight loss in head-to-head comparisons, Saxenda remains a highly effective option, particularly for patients who may not tolerate higher-potency GLP-1 agonists or who prefer daily dosing control.

Real-World Weight Loss Outcomes With Wegovy Or Saxenda

Beyond controlled trial environments, real-world evidence studies confirm that both wegovy or saxenda deliver clinically meaningful weight loss when prescribed appropriately. A 2023 UK retrospective cohort analysis found that 12-month persistence rates were 68% for semaglutide weekly injections versus 54% for daily liraglutide, with corresponding average weight reductions of 12.3% and 7.1% respectively [3]. These real-world figures are slightly lower than trial data, reflecting the challenges of adherence, prescription continuity, and lifestyle maintenance outside controlled research settings.

Side Effects: Wegovy Or Saxenda Tolerability Comparison

When evaluating wegovy or saxenda for side effect profiles, both medications share common GLP-1 class adverse events, predominantly gastrointestinal in nature. Nausea, diarrhoea, constipation, vomiting, and abdominal discomfort are reported with both treatments, typically most pronounced during dose escalation phases [1][2]. Clinical trial data indicates that approximately 44% of Wegovy patients and 39% of Saxenda patients experienced nausea, though most cases were mild to moderate and diminished over time with continued treatment.

The key tolerability difference between wegovy or saxenda relates to dosing frequency and titration flexibility. Saxenda's daily administration allows for more granular dose adjustments if side effects emerge, and its shorter half-life means symptoms resolve more quickly upon dose reduction or discontinuation. Wegovy's weekly dosing provides convenience but requires patience during titration, as each dose adjustment affects the body for approximately one week. At Cured Pharmacy, our prescribers carefully assess medical history, previous GLP-1 experience, and patient preferences to recommend the most appropriate option, with close monitoring during the initial treatment phase.

Managing Side Effects With Wegovy Or Saxenda

Successful management of side effects with wegovy or saxenda requires gradual dose escalation, dietary modifications, and clear patient education. We advise patients to start with smaller meal portions, avoid high-fat foods during initial weeks, stay well-hydrated, and take the injection at a consistent time to establish routine. If nausea persists, remaining at the current dose for an additional week before escalating often improves tolerance. Severe or persistent side effects should always be discussed with your prescriber, who may adjust your treatment plan accordingly.

Dosing Schedule: Wegovy Or Saxenda Administration

The dosing schedule represents one of the most practical differences when choosing between wegovy or saxenda. Wegovy follows a structured monthly escalation protocol: 0.25mg weekly for 4 weeks, 0.5mg weekly for 4 weeks, 1mg weekly for 4 weeks, 1.7mg weekly for 4 weeks, then maintenance at 2.4mg weekly [1]. This gradual titration minimises gastrointestinal side effects while allowing the body to adapt to increasing GLP-1 receptor stimulation. Each Wegovy pen is pre-filled with a single dose, colour-coded by strength, and administered via subcutaneous injection into the abdomen, thigh, or upper arm.

Saxenda employs a faster initial titration over 5 days: 0.6mg daily on days 1-7, 1.2mg daily on days 8-14, 1.8mg daily on days 15-21, 2.4mg daily on days 22-28, then maintenance at 3mg daily [2]. The Saxenda pen is multi-dose, allowing patients to dial the precise dose each day. This daily administration requires greater commitment but offers flexibility for patients who want more frequent dose control. When comparing wegovy or saxenda for lifestyle fit, we find that professionals with consistent weekly routines often prefer Wegovy, while patients who value daily control or have concerns about weekly peaks favour Saxenda.

Cost Analysis: Wegovy Or Saxenda UK Pricing

Cost is frequently a decisive factor when patients compare wegovy or saxenda for long-term weight management. At Cured Pharmacy, Wegovy is available from £69.00 per weekly injection, while Saxenda is priced from £69.00 per multi-dose pen (approximately 6 days' supply at maintenance dose). Over a 4-week period, Wegovy costs approximately £69.00 (4 weekly injections), whereas Saxenda costs approximately £69.00 (5 pens for 30 days at 3mg daily). These figures represent transparent upfront pricing, with no hidden consultation fees — our UK-registered prescribers provide free online assessments completed in under 3 minutes.

When evaluating wegovy or saxenda from a cost-effectiveness perspective, it's essential to consider not just price per unit but also efficacy, adherence, and total treatment duration required to achieve goals. While Wegovy carries a slightly higher monthly cost, its superior average weight loss in trials may mean patients reach target weight sooner, potentially reducing total treatment expenditure. Conversely, Saxenda's lower entry price and daily dosing flexibility may suit patients who prefer incremental commitment or who are trialling GLP-1 therapy for the first time. Both treatments qualify for our £20 discount on first orders using code Weightlossnew, and we guarantee the lowest UK prices for genuine licensed medications.

Insurance And NHS Availability For Wegovy Or Saxenda

NHS prescription of wegovy or saxenda is currently limited by strict eligibility criteria through specialist weight management services, with significant regional variation and waiting lists often exceeding 12 months. NICE guidelines recommend GLP-1 agonists for weight management only after intensive lifestyle interventions have been attempted, and typically require BMI ≥35 with comorbidities or BMI ≥30 with specific conditions [4]. Private prescription through registered UK pharmacies like Cured Pharmacy offers immediate access following clinical assessment, with transparent pricing and next-day delivery, making treatment accessible to patients who meet clinical criteria but face NHS capacity constraints.

Who Should Choose Wegovy Or Saxenda?

Determining whether wegovy or saxenda is more appropriate depends on individual clinical circumstances, lifestyle factors, and treatment goals. Wegovy may be particularly suitable for patients seeking maximum weight loss efficacy, those who prefer once-weekly administration, individuals with established GLP-1 tolerance from previous treatments, and patients with higher baseline BMI where more intensive intervention is warranted. The longer half-life and higher potency of semaglutide make Wegovy the preferred choice in our clinical practice for patients who have plateaued on other weight loss treatments or who require significant weight reduction for health reasons.

Saxenda may be more appropriate for patients new to GLP-1 therapy who want to start with a lower-intensity option, those who prefer daily dosing control and flexibility, individuals with previous GLP-1 side effect concerns who value the shorter half-life, and patients for whom cost is a primary consideration. When advising patients on wegovy or saxenda selection, our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that both are highly effective MHRA-licensed treatments, and the optimal choice emerges from a comprehensive clinical assessment considering medical history, concurrent medications, weight loss goals, and personal preferences. All patients must complete an online consultation with our UK-registered prescribers, who will recommend the most clinically appropriate treatment based on individual circumstances.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 15 August 2026]
3. Gallagher, C., Mahony, R., Mohan, B., McAuliffe, C., & Tobin, A. M. (2023). Real-world persistence and effectiveness of GLP-1 receptor agonists for weight management: A retrospective cohort study. Obesity Medicine, 38, 100485. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE guideline. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.